Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 3.6% – Should You Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was up 3.6% during trading on Wednesday . The stock traded as high as $7.34 and last traded at $7.24. Approximately 13,659,767 shares traded hands during trading, an increase of 100% from the average daily volume of 6,818,902 shares. The stock had previously closed at $6.99.

Analysts Set New Price Targets

Several brokerages have issued reports on RXRX. Leerink Partners dropped their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research note on Tuesday, September 3rd. Jefferies Financial Group dropped their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. Finally, Needham & Company LLC restated a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $9.25.

Recursion Pharmaceuticals Stock Performance

The company has a fifty day moving average price of $6.80 and a 200 day moving average price of $7.16. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The stock has a market cap of $2.20 billion, a P/E ratio of -5.01 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The business had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business’s quarterly revenue was up 147.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.43) EPS. On average, equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $7.64, for a total value of $87,455.08. Following the completion of the sale, the director now owns 7,066,113 shares in the company, valued at $53,985,103.32. This represents a 0.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Michael Secora sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the transaction, the chief financial officer now directly owns 1,499,631 shares in the company, valued at $11,487,173.46. The trade was a 0.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 101,788 shares of company stock worth $682,691. Insiders own 15.75% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Axxcess Wealth Management LLC grew its holdings in shares of Recursion Pharmaceuticals by 4.3% in the third quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock valued at $289,000 after acquiring an additional 1,795 shares in the last quarter. Green Alpha Advisors LLC increased its position in shares of Recursion Pharmaceuticals by 2.9% during the 3rd quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company’s stock valued at $427,000 after purchasing an additional 1,800 shares during the last quarter. Interchange Capital Partners LLC raised its stake in shares of Recursion Pharmaceuticals by 7.3% during the 2nd quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock worth $268,000 after purchasing an additional 2,349 shares during the period. Amalgamated Bank boosted its holdings in shares of Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after buying an additional 2,459 shares during the last quarter. Finally, Victory Capital Management Inc. grew its position in Recursion Pharmaceuticals by 13.5% during the second quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock valued at $164,000 after buying an additional 2,598 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.